Pharmaceutical

Sildenafil citrate by XOMA Royalty for Female Hypoactive Sexual Desire Disorder: Likelihood of Approval

Sildenafil citrate is under clinical development by XOMA Royalty and currently in Phase II for Female Hypoactive Sexual Desire Disorder.

Sep 10, 2024 - 04:00
Sildenafil citrate is under clinical development by XOMA Royalty and currently in Phase II for Female Hypoactive Sexual Desire Disorder.
Read the original article

Tags:

Previous Article

CMN-005 by CoImmune for Mantle Cell Lymphoma: Likelihood of Approval

Next Article

GSK’s Asthma Drug Meets Primary Endpoint in Phase 3 Trial

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pipelines from high school to health care jobs to be created by new Bloomberg Philanthropies initiative

STAT+: Pipelines from high school to health care jobs t...

Jan 18, 2024

Parenteral Solutions in Contract Manufacturing for the Pharmaceutical Industry 

Parenteral Solutions in Contract Manufacturing for the ...

Oct 16, 2024

STAT+: FDA panel unanimously endorses Eisai’s Alzheimer’s drug

STAT+: FDA panel unanimously endorses Eisai’s Alzheimer...

Jun 10, 2023